Opendata, web and dolomites

BRCA-ERC SIGNED

Understanding cancer development in BRCA 1/2 mutation carriers for improved Early detection and Risk Control

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BRCA-ERC project word cloud

Explore the words cloud of the BRCA-ERC project. It provides you a very rough idea of what is the project "BRCA-ERC" about.

establishing    biologists    advocacy    mechanistically    chronic    breast    cells    screening    re    autonomous    immunologists    blood    clinician    ideally    functionalists    applicable    principles    risk    largely    mutation    epigenome    initiating    lack    consequently    centered    assembled    reset    fundamental    organs    origin    scientists    possibly    direct    pioneering    cohort    carriers    medical    multifactorial    uncover    recent    cervical    mutations    net    fatal    consequence    buccal    core    groups    effect    overtaking    placed    cell    efficacy    epigenetic    outcome    brca    samples    surgery    scientific    monitor    trigger    women    distant    demonstrates    powerful    patient    extremely    mortality    human    ovarian    cancers    interdisciplinary    cancer    predictors    disease    team    hypothesis    newly    tissues    normal    breakthrough    germline    reducing    computational    neutralise    controls    diseases    preventative    identity    multicellular    brca1    linked    medicine    cardiovascular   

Project "BRCA-ERC" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITY COLLEGE LONDON 

Organization address
address: GOWER STREET
city: LONDON
postcode: WC1E 6BT
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 2˙497˙841 €
 EC max contribution 2˙497˙841 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-ADG
 Funding Scheme ERC-ADG
 Starting year 2017
 Duration (year-month-day) from 2017-09-01   to  2022-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY COLLEGE LONDON UK (LONDON) coordinator 2˙264˙589.00
2    UNIVERSITY COLLEGE LONDON HOSPITALSNHS FOUNDATION TRUST UK (LONDON) participant 233˙251.00

Map

 Project objective

Recent evidence demonstrates that cancer is overtaking cardiovascular disease as the number one cause of mortality in Europe. This is largely due to the lack of preventative measures for common (e.g. breast) or highly fatal (e.g. ovarian) human cancers. Most cancers are multifactorial in origin. The core hypothesis of this research programme is that the extremely high risk of BRCA1/2 germline mutation carriers to develop breast and ovarian cancer is a net consequence of cell-autonomous (direct effect of BRCA mutation in cells at risk) and cell non-autonomous (produced in distant organs and affecting organs at risk) factors which both trigger epigenetic, cancer-initiating effects. The project’s aims are centered around the principles of systems medicine and built on a large cohort of BRCA mutation carriers and controls who will be offered newly established cancer screening programmes. We will uncover how ‘cell non-autonomous’ factors work, provide detail on the epigenetic changes in at-risk tissues and investigate whether these changes are mechanistically linked to cancer, study whether we can neutralise this process and measure success in the organs at risk, and ideally in easy to access samples such as blood, buccal and cervical cells. In my Department for Women’s Cancer we have assembled a powerful interdisciplinary team including computational biologists, functionalists, immunologists and clinician scientists linked to leading patient advocacy groups which is extremely well placed to lead this pioneering project to develop the fundamental understanding of cancer development in women with BRCA mutations. To reset the epigenome, re-establishing normal cell identity and consequently reducing cancer risk without the need for surgery and being able to monitor the efficacy using multicellular epigenetic outcome predictors will be a major scientific and medical breakthrough and possibly applicable to other chronic diseases.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRCA-ERC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BRCA-ERC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

HyperBio (2019)

Vis-NIR Hyperspectral imaging for biomaterial quality control

Read More  

KineTic (2020)

New Reagents for Quantifying the Routing and Kinetics of T-cell Activation

Read More  

SLAMseq (2019)

SLAMseq: Temporal resolution in gene expression profiling across multiple platforms

Read More